Indeed, in patients with nonsmall cell lung cancer (NSCLC), high serum chemerin levels were shown to be associated with shorter overall survival [22], whereas high chemerin expression in tumor as assessed by immunohistology was found to be associated with better survival [23]. Here, RARRES2 is linked to non-small cell lung carcinoma.